The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.
Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor (PDE5i). Since PDE5i is known to relax smooth muscle cells, it is suggested that PDE5i may dilate cerebral vessels and lead to an increase in cerebral blood flow. The main mechanism of subcortical vascular cognitive impairment are hypoperfusion of the brain. Therefore, in this study, the investigators will investigate whether Udenafil can increase cerebral blood flow and also lower peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
80
Zydena (Udenafil) 100 mg, one time
Placebo
Samsung Medical Center
Seoul, South Korea
Cerebral blood flow
Measured by Near-infrared spectroscopy (NIRS)
Time frame: One hour after the administration of the medication
Peripheral blood viscosity
Measured from whole blood
Time frame: One hour after the administration of the medication
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.